Dr. Nolan Sigal resigns from Aileron board; Nasdaq confirms compliance with annual meeting rule

Rein Therapeutics, Inc.

Dr. Nolan Sigal resigned from Board and Nominating Committee effective February 29, 2024; no disagreement cited.
Company received Nasdaq letter confirming regained compliance with Listing Rule 5620 (annual meeting requirement) on February 29, 2024.
No replacement director announced; Board size reduced.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nolan Sigal

member of the Board of Directors

RNTX · Rein Therapeutics, Inc.

Effective: 2024-02-29
Filed: March 1, 2024, 6:59 PM ET

On February 29, 2024, Nolan Sigal, M.D., Ph.D., notified Aileron Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nolan Sigal resigned as member of the Board of Directors at Rein Therapeutics, Inc..

Action: resigned
Role: member of the Board of Directors

Exact text from the filing

On February 29, 2024, Nolan Sigal, M.D., Ph.D., notified Aileron Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately.

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-055936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.